Skip to Content

Suvorexant Pregnancy and Breastfeeding Warnings

Suvorexant is also known as: Belsomra

Medically reviewed on September 19, 2018

Suvorexant Pregnancy Warnings

Suvorexant in pregnant rats at exposures approximately 25 times that in humans resulted in decreased fetal body weight. Suvorexant in pregnant rabbits at exposures approximately 40 times that in humans resulted in premature sacrifice of pregnant animals. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

See references

Suvorexant Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

The effects in the nursing infant are unknown.

Suvorexant and a hydroxyl-suvorexant metabolite were excreted in rat milk at levels higher (9 and 1.5 times, respectively) than that in maternal plasma.

See references

References for pregnancy information

  1. "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.

References for breastfeeding information

  1. "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide